Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA

• Published in: PharmacoEconomics 2023-06, Vol.41 (6), p.709-718
• Main Authors: Masurkar, Prajakta P., Damgacioglu, Haluk, Deshmukh, Ashish A., Trivedi, Meghana V.
• Format: Article
• Language: English
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Cancer therapies; Care and treatment; Cell cycle; Clinical trials; Cost analysis; Cost benefit analysis; Cost-Effectiveness Analysis; Cyclin-Dependent Kinase 4 - therapeutic use; Cyclin-dependent kinases; Endocrine therapy; Epidermal growth factor; Evaluation; FDA approval; Female; Health Administration; Health care policy; Health Economics; Humans; Inhibitors; Kinases; Letrozole - therapeutic use; Medical prognosis; Medicare; Medicine; Medicine & Public Health; Metastasis; Neutropenia; Original Research Article; Patient outcomes; Pharmacoeconomics and Health Outcomes; Postmenopause; Public Health; Quality of Life Research; Receptor, ErbB-2 - metabolism; Sensitivity analysis; United States; Womens health
• ISSN: 1170-7690; 1179-2027
• DOI: 10.1007/s40273-023-01245-y

Background and Objective Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors improve progression-free survival when combined with endocrine therapies in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. However, the comparative cost effectiveness of utilizing three US Food and Drug Administration-approved CDK4/6 inhibitors is unknown. Therefore, we aimed to evaluate the cost effectiveness of individual CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) with letrozole versus letrozole monotherapy in the first-line treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the USA. Methods We constructed a Markov-based decision-analytic model to evaluate the cost effectiveness of CDK4/6 inhibitors plus endocrine therapies over a 40-year lifetime from a third-party payer perspective. The model incorporated health states (progression-free disease, progressive disease, and death), major adverse events (neutropenia), and cancer-specific and all-cause mortality. Using clinical efficacy and quality-of-life scores (utility) data from clinical trials, we estimated quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios using Medicare charges reported in US dollars per 2022 valuation and a discount rate of 3% applied to costs and outcomes. We performed deterministic and probabilistic sensitivity analyses to evaluate parametric and decision uncertainty. Results Compared to letrozole, the model estimated an increase of 5.72, 5.87, and 6.39 in QALYs and costs of $799,178, $788,168, and $741,102 in combining palbociclib, ribociclib, and abemaciclib plus letrozole, respectively. Palbociclib or ribociclib plus letrozole were dominated by abemaciclib plus letrozole. Compared with letrozole, abemaciclib plus letrozole resulted in an incremental cost-effectiveness ratio of $457,538 per QALY with an incremental cost of $553,621 and an incremental QALY gain of 1.21. The results were sensitive to the cost of abemaciclib, disease progression utility, and patients’ age. Conclusions At a willingness to pay of $100,000/QALY gained, our model predicts that combining CDK4/6 inhibitors plus letrozole is not cost effective with a marginal increase in QALYs at a high cost. Lowering the cost of these drugs or identifying patients who can receive maximal benefit from CDK4/6 inhibitors would improve the value of this regimen in patients.